Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 322

Results For "ENT"

9421 News Found

ALBIS unveils next-gen healthcare materials at COMPAMED 2025
News | November 16, 2025

ALBIS unveils next-gen healthcare materials at COMPAMED 2025

ALBIS will present a selection of advanced materials from its broad healthcare portfolio


Abbott unveils new diabetes care formula amid rising global diabetes crisis
News | November 16, 2025

Abbott unveils new diabetes care formula amid rising global diabetes crisis

The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health


Glenmark posts 72.2% jump in Q2 FY net profit at Rs. 610.4 Cr YoY
News | November 16, 2025

Glenmark posts 72.2% jump in Q2 FY net profit at Rs. 610.4 Cr YoY

EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025


Kilitch Drugs H! FY26 PAT up 18% YoY to Rs. 10.30 Cr
News | November 16, 2025

Kilitch Drugs H! FY26 PAT up 18% YoY to Rs. 10.30 Cr

Total income for the period stood at Rs. 7101.28 crore


Medico Remedies gets GMP compliance certificate from SMDC, Ukraine
News | November 16, 2025

Medico Remedies gets GMP compliance certificate from SMDC, Ukraine

SMDC is a participating authority under Pharmaceutical Inspection Cooperation Scheme (PIC/S)


Amcor launches ultra-light Shadow roll-on for next-gen beauty branding
Packaging | November 16, 2025

Amcor launches ultra-light Shadow roll-on for next-gen beauty branding

The new shadow roll-on delivers strong on-shelf presence with its modern rounded-base design


Cenmed and Curavit team up to revolutionize clinical trial logistics
Supply Chain | November 16, 2025

Cenmed and Curavit team up to revolutionize clinical trial logistics

This collaboration turns kitting into a strategic advantage for sponsors and sites


Merck to acquire Cidara Therapeutics for $9.2 billion
Biotech | November 15, 2025

Merck to acquire Cidara Therapeutics for $9.2 billion

Diversifying its portfolio to include late-phase antiviral agent